Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

Crypto@FirstSquawk on XFiled 31 h ago

A post by @FirstSquawk on X.

Open the post on XPosted by @FirstSquawk on x.com

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Eli Lilly said its obesity drugs demonstrated weight-loss results in clinical studies, according to a Reuters report relayed by First Squawk. The announcement centers on the company's obesity franchise, though the headline did not specify which candidates, trial sizes, or the magnitude of weight reduction. The update matters because Lilly's weight-loss portfolio is a key growth driver for the drugmaker and a major focus for investors tracking demand for GLP-1 treatments. Watch for the full trial data, including detailed efficacy and safety figures, and any implications for the competitive positioning of Lilly's obesity drugs.

Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.

Named in this story

A linked name opens that asset's sentiment page.